Clinical Trials Browser

Phase 2 × Janus Kinase Inhibitors × 90 days × Clear all

NCT07228624 2026-02-19

Ruxolitinib Before, During and After Hematopoietic Cell Transplant in Older Patients With Myelofibrosis and Myelodysplastic Syndrome/Myeloproliferative Neoplasm Overlap Syndromes

Phase 2 Recruiting

Myelodysplastic-Myeloproliferative Diseases, Primary Myelofibrosis